Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DXC Technology CoDXC · Entity 4594 | Director | August 20, 2021 | August 24, 2021 |
| Empery Digital Inc.VLCN · Entity 21 | Director | July 17, 2025 | July 21, 2025 |
| KIMBERLY CLARK CORPKMB · Entity 3103 | Director | January 03, 2022 | January 05, 2022 |
| PFIZER INCPFE · Entity 2863 | Director · Executive Chairman | March 04, 2019 | March 06, 2019 |
| Population Health Investment Co., Inc.PHIC · Entity 136038 | Director · Executive Chairman | November 17, 2020 | November 17, 2020 |
| Viatris IncVTRS · Entity 3277 | Director | March 21, 2022 | March 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DXC Technology Co
Report date August 20, 2021 · Filed August 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,800 |
Reported balance
After 2021-08-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-08-20 · Grant · Acquired 12,700 · Balance 48,800 F1: Award of restricted stock units (RSUs). Each RSU entitles the reporting person to receive one share of common stock. The RSUs will vest on the earlier of (i) one year from the grant date, or (ii) at the next annual meeting of stockholders. The RSUs will settle on the vesting date or, if the director has elected to defer settlement, on the date or event elected by the director. F2: Amount reported includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of restricted stock units (RSUs). Each RSU entitles the reporting person to receive one share of common stock. The RSUs will vest on the earlier of (i) one year from the grant date, or (ii) at the next annual meeting of stockholders. The RSUs will settle on the vesting date or, if the director has elected to defer settlement, on the date or event elected by the director.
F2: Amount reported includes unvested RSUs.
Empery Digital Inc.
Report date July 17, 2025 · Filed July 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
After 2025-07-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-21 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares of common stock were purchased by the Reporting Person in the Issuer's recently announced private placement with certain accredited and institutional investors, which closed on July 21, 2025. F2: The shares of common stock were purchased by the Ian Charles Read Revocable Trust the ("Trust"). The Reporting Person is the trustee of the trust and may be deemed to have sole voting and dispositive power over the shares held by the Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2035-07-17 | Direct | 298,802 |
Reported balance
After 2025-07-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-17 · Grant · Acquired 298,802 · Balance 298,802 F3: The stock options vest based upon the daily volume weighted average price ("VWAP") of the Issuer's common stock, vesting as to 20% of the underlying shares of common stock upon the VWAP reaching $10 and then in incremental 20% installments until becoming fully vested upon a VWAP of $30. All vesting is subject to the approval by the Issuer's stockholder of a new stock option plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were purchased by the Reporting Person in the Issuer's recently announced private placement with certain accredited and institutional investors, which closed on July 21, 2025.
F2: The shares of common stock were purchased by the Ian Charles Read Revocable Trust the ("Trust"). The Reporting Person is the trustee of the trust and may be deemed to have sole voting and dispositive power over the shares held by the Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3: The stock options vest based upon the daily volume weighted average price ("VWAP") of the Issuer's common stock, vesting as to 20% of the underlying shares of common stock upon the VWAP reaching $10 and then in incremental 20% installments until becoming fully vested upon a VWAP of $30. All vesting is subject to the approval by the Issuer's stockholder of a new stock option plan.
KIMBERLY CLARK CORP
Report date January 03, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 37,206 |
Reported balance
After 2022-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-03 · Grant · Acquired 1,299 · Balance 37,206 F1: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F2: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors.
F2: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock.
PFIZER INC
Report date March 04, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,109,202 |
Ending reported balance
After 2019-03-04 transaction · row 26
26 source rows · reconciled sequenceRow 1 · 2019-03-04 · Sale · Disposed 3,722 · Balance 1,635,558 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 2 · 2019-03-04 · Sale · Disposed 4,258 · Balance 1,631,300 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 3 · 2019-03-04 · Sale · Disposed 4,392 · Balance 1,626,908 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 4 · 2019-03-04 · Sale · Disposed 4,489 · Balance 1,622,419 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 5 · 2019-03-04 · Sale · Disposed 5,812 · Balance 1,616,607 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 6 · 2019-03-04 · Sale · Disposed 6,284 · Balance 1,610,323 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 7 · 2019-03-04 · Sale · Disposed 6,960 · Balance 1,603,363 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 8 · 2019-03-04 · Sale · Disposed 7,584 · Balance 1,595,779 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 9 · 2019-03-04 · Sale · Disposed 8,427 · Balance 1,587,352 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 10 · 2019-03-04 · Sale · Disposed 10,725 · Balance 1,576,627 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 11 · 2019-03-04 · Sale · Disposed 11,804 · Balance 1,564,823 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 12 · 2019-03-04 · Sale · Disposed 11,908 · Balance 1,552,915 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 13 · 2019-03-04 · Sale · Disposed 12,457 · Balance 1,540,458 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 14 · 2019-03-04 · Sale · Disposed 12,623 · Balance 1,527,835 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 15 · 2019-03-04 · Sale · Disposed 12,787 · Balance 1,515,048 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 16 · 2019-03-04 · Sale · Disposed 12,971 · Balance 1,502,077 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 17 · 2019-03-04 · Sale · Disposed 13,275 · Balance 1,488,802 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 18 · 2019-03-04 · Sale · Disposed 14,739 · Balance 1,474,063 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 19 · 2019-03-04 · Sale · Disposed 16,537 · Balance 1,457,526 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 20 · 2019-03-04 · Sale · Disposed 21,624 · Balance 1,435,902 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 21 · 2019-03-04 · Sale · Disposed 28,599 · Balance 1,407,303 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 22 · 2019-03-04 · Sale · Disposed 34,216 · Balance 1,373,087 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 23 · 2019-03-04 · Sale · Disposed 52,878 · Balance 1,320,209 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 24 · 2019-03-04 · Sale · Disposed 69,362 · Balance 1,250,847 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 25 · 2019-03-04 · Sale · Disposed 69,433 · Balance 1,181,414 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. Row 26 · 2019-03-04 · Sale · Disposed 72,212 · Balance 1,109,202 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018. |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 11,442 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 27
Holding and transaction disclosures are not merged.
1 source rowRow 27 · Balance 11,442 |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018.
Population Health Investment Co., Inc.
Report date November 17, 2020 · Filed November 17, 2020
This filing explicitly reported no securities owned.
Viatris Inc
Report date March 21, 2022 · Filed March 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,497 |
Reported balance
After 2022-03-21 transaction · row 1
1 source rowRow 1 · 2022-03-21 · Exercise / conversion · Acquired 166 · Balance 14,497 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 2 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 165.5224 |
Reported balance
After 2022-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-21 · Grant · Acquired 165.5224 · Balance 165.5224 F2: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-03-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-21 · Exercise / conversion · Disposed 165.5224 · Balance 0 F2: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 2 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Represents dividend equivalent units (DEUs) that accrued with respect to RSUs previously granted on March 2, 2021. The DEUs vested upon accrual as the underlying RSUs had previously vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2012 Filed Aug 1, 2012 22:30 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 265 | $24.04 | $6,370.60 |
DisclosureSEC source: 0001225208-12-017100 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,443 Underlying: Common Stock · 265 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 13, 2012 Filed Jul 17, 2012 13:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 346 | $22.81 | $7,892.26 |
DisclosureSEC source: 0001225208-12-016329 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,178 Underlying: Common Stock · 346 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 12:15 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 315 | $23.00 | $7,245.00 |
DisclosureSEC source: 0001225208-12-015288 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,832 Underlying: Common Stock · 315 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2012 Filed Jun 19, 2012 18:05 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 343 | $22.61 | $7,755.23 |
DisclosureSEC source: 0001225208-12-014565 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,517 Underlying: Common Stock · 343 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2012 Filed Jun 1, 2012 21:35 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 382 | $21.87 | $8,354.34 |
DisclosureSEC source: 0001225208-12-013546 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,174 Underlying: Common Stock · 382 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2012 Filed May 16, 2012 19:32 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,420 | $22.30 | $31,666.00 |
DisclosureSEC source: 0001225208-12-012560 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,792 Underlying: Common Stock · 1,420 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2012 Filed May 1, 2012 20:57 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 469 | $22.90 | $10,740.10 |
DisclosureSEC source: 0001225208-12-010665 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,372 Underlying: Common Stock · 469 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 13, 2012 Filed Apr 16, 2012 22:03 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 317 | $21.85 | $6,926.45 |
DisclosureSEC source: 0001225208-12-009837 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,903 Underlying: Common Stock · 317 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 18:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 369 | $22.65 | $8,357.85 |
DisclosureSEC source: 0001225208-12-008922 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,586 Underlying: Common Stock · 369 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2012 Filed Mar 19, 2012 12:47 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 17,582 | $21.91 | $385,221.62 |
DisclosureSEC source: 0001225208-12-007858 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,217 Underlying: Common Stock · 17,582 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 16:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 165 | $21.13 | $3,486.45 |
DisclosureSEC source: 0001225208-12-006374 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,635 Underlying: Common Stock · 165 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:01 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 33,885 | $21.18 | $717,684.30 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 878,697 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2012 Filed Feb 27, 2012 23:01 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 75,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,582 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 668,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · derivative · entry 7 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,724 Underlying: Common Stock · 668,724 shares Expires 2019-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 788,835 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,835 Underlying: Common Stock · 788,835 shares Expires 2017-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2012 Filed Feb 27, 2012 23:01 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 153,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-005637 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 837,331 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| December 29, 2011 Filed Dec 30, 2011 21:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 326 | $21.71 | $7,077.46 |
DisclosureSEC source: 0001225208-11-027099 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,570 Underlying: Common Stock · 326 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2011 Filed Dec 19, 2011 17:01 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 307 | $21.14 | $6,489.98 |
DisclosureSEC source: 0001225208-11-026536 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,244 Underlying: Common Stock · 307 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2011 Filed Dec 1, 2011 22:21 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 372 | $20.07 | $7,466.04 |
DisclosureSEC source: 0001225208-11-025588 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,937 Underlying: Common Stock · 372 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2011 Filed Nov 16, 2011 23:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,354 | $19.87 | $26,903.98 |
DisclosureSEC source: 0001225208-11-024989 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,565 Underlying: Common Stock · 1,354 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2011 Filed Nov 1, 2011 23:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 379 | $19.26 | $7,299.54 |
DisclosureSEC source: 0001225208-11-024119 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,211 Underlying: Common Stock · 379 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 14, 2011 Filed Oct 18, 2011 19:03 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 349 | $19.04 | $6,644.96 |
DisclosureSEC source: 0001225208-11-023476 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,832 Underlying: Common Stock · 349 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2011 Filed Oct 4, 2011 14:46 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 445 | $17.68 | $7,867.60 |
DisclosureSEC source: 0001225208-11-022591 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,483 Underlying: Common Stock · 445 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2011 Filed Sep 16, 2011 20:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 437 | $18.49 | $8,080.13 |
DisclosureSEC source: 0001225208-11-021834 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,038 Underlying: Common Stock · 437 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 19:17 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 324 | $18.98 | $6,149.52 |
DisclosureSEC source: 0001225208-11-021089 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,601 Underlying: Common Stock · 324 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2011 Filed Aug 16, 2011 21:41 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,591 | $18.34 | $29,178.94 |
DisclosureSEC source: 0001225208-11-020052 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,277 Underlying: Common Stock · 1,591 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 29, 2011 Filed Aug 2, 2011 16:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 350 | $19.25 | $6,737.50 |
DisclosureSEC source: 0001225208-11-019086 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,686 Underlying: Common Stock · 350 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2011 Filed Jul 19, 2011 14:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 395 | $19.75 | $7,801.25 |
DisclosureSEC source: 0001225208-11-018378 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,336 Underlying: Common Stock · 395 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2011 Filed Jul 5, 2011 14:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 299 | $20.60 | $6,159.40 |
DisclosureSEC source: 0001225208-11-017226 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,941 Underlying: Common Stock · 299 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2011 Filed Jun 16, 2011 19:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 462 | $20.19 | $9,327.78 |
DisclosureSEC source: 0001225208-11-016426 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,642 Underlying: Common Stock · 462 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 31, 2011 Filed Jun 1, 2011 18:18 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 310 | $21.45 | $6,649.50 |
DisclosureSEC source: 0001225208-11-015550 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,180 Underlying: Common Stock · 310 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 13, 2011 Filed May 16, 2011 17:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,321 | $20.92 | $27,635.32 |
DisclosureSEC source: 0001225208-11-014355 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,870 Underlying: Common Stock · 1,321 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 29, 2011 Filed May 2, 2011 21:33 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 300 | $20.97 | $6,291.00 |
DisclosureSEC source: 0001225208-11-012793 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,549 Underlying: Common Stock · 300 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2011 Filed Apr 18, 2011 18:54 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 355 | $20.53 | $7,288.15 |
DisclosureSEC source: 0001225208-11-011827 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,249 Underlying: Common Stock · 355 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2011 Filed Apr 4, 2011 16:21 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 360 | $20.31 | $7,311.60 |
DisclosureSEC source: 0001225208-11-010800 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,894 Underlying: Common Stock · 360 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2011 Filed Mar 16, 2011 20:09 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 8,322 | $19.76 | $164,442.72 |
DisclosureSEC source: 0001225208-11-009807 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,534 Underlying: Common Stock · 8,322 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 189 | $19.24 | $3,636.36 |
DisclosureSEC source: 0001225208-11-007979 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,212 Underlying: Common Stock · 189 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 420,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 7 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2018-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to 125% of the closing price of Pfizer common stock on December 3, 2010, which was the last business day before Mr. Read was elected President and Chief Executive Officer of the Company. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to 125% of the closing price of Pfizer common stock on December 3, 2010, which was the last business day before Mr. Read was elected President and Chief Executive Officer of the Company. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 483,559 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,559 Underlying: Common Stock · 483,559 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 584,112 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 5 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,112 Underlying: Common Stock · 584,112 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 4,239 | $18.90 | $80,117.10 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,837 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 11,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,076 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 160,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,105 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 22:18 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 290 | $17.51 | $5,077.90 |
DisclosureSEC source: 0001225208-11-000269 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,197 Underlying: Common Stock · 290 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2010 Filed Dec 17, 2010 22:28 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 312 | $17.08 | $5,328.96 |
DisclosureSEC source: 0001225208-10-027433 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,907 Underlying: Common Stock · 312 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2010 Filed Dec 2, 2010 00:16 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 255 | $16.30 | $4,156.50 |
DisclosureSEC source: 0001225208-10-026044 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,595 Underlying: Common Stock · 255 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 15, 2010 Filed Nov 16, 2010 23:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 1,364 | $16.75 | $22,847.00 |
DisclosureSEC source: 0001225208-10-025023 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,340 Underlying: Common Stock · 1,364 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 29, 2010 Filed Nov 1, 2010 20:18 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 248 | $17.42 | $4,320.16 |
DisclosureSEC source: 0001225208-10-023829 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,976 Underlying: Common Stock · 248 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2010 Filed Oct 18, 2010 23:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 240 | $17.75 | $4,260.00 |
DisclosureSEC source: 0001225208-10-023191 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,728 Underlying: Common Stock · 240 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 19:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 310 | $17.17 | $5,322.70 |
DisclosureSEC source: 0001225208-10-021678 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,488 Underlying: Common Stock · 310 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.